BIO-Europe 2026 has ended. This guide stays up as the record of who was there. See upcoming conferences

Who’s Going to BIO‑Europe 2026

Nov 9–11, 2026 Cologne, Germany ~5.8k attendees Website

473 companies and 473 speakers at BIO-Europe 2026, a ~5,800-person, almost entirely industry partnering meeting of European biotech and pharma dealmakers and investors. As of Nov 10, 2026.

Format
Track
Top represented
Showing 1–8 of 473 organizations
OrganizationBIO-Europe 2026 Attendance
Merck KGaA
Darmstadt, Germany
◆Platinum Sponsor
Large pharmaPlatinum sponsor
Science and technology company active in healthcare, life science and electronics; operates as EMD Serono and MilliporeSigma in North America.
Talk
Mon Nov 9
09:00–10:00
Building Your BD Career: What Really Moves the Needle
What it takes to build a career in drug licensing and partnership deals, from scientific and financial skills to credibility and contacts.
with BD&L Peers Community, Thuja Capital, Tubulis +1 more
Talk
Mon Nov 9
15:00–16:15
Merck's EMEA Advance Biotech Grant Program
Five young biotech companies pitch their science to Merck, competing for a grant that helps them bring a product to market.
with Stemmatters, M Ventures, ConvEyXO +4 more
Panel
Mon Nov 9
13:00–13:45
Open Innovation in Action: How Pharma Is Rewiring the Drug Discovery Ecosystem
How big drug companies share their collections of test molecules and data with outside scientists to speed up early drug discovery.
with MichBio, XGEN Venture, Boehringer Ingelheim
Panel
Tue Nov 10
14:00–14:45
Immunology under the microscope: New frontiers
What is new in drugs for autoimmune and inflammatory diseases: emerging targets, recent trial results, and where companies are investing and partnering.
with MRM Health, Hansa Biopharma, Claris Ventures
Talk
Tue Nov 10
09:15–09:30
Pharma Presentation: Merck
Merck's three businesses: medicines for diseases such as multiple sclerosis and cancer, tools for scientists, and technology for electronics.
Panel
Tue Nov 10
16:00–16:45
Unlocking Clinical Trial Systems
How EU clinical trial rules and a planned EU biotech law affect trial approval times, and whether Europe can speed up safely.
with R Kupiec Consulting, Parexel, AstraZeneca
Panel
Wed Nov 11
09:00–09:45
From NAMs (New Approach Methodologies) Innovation to Regulatory acceptance: Accelerating human-relevant modelling
How lab models built on human biology, from organs-on-chips to AI computer models, can speed drug development and win regulators' acceptance.
with FRESCI, TissUse, European Commission +2 more
Bayer
Leverkusen, Germany
◆Platinum Sponsor
Large pharmaPlatinum sponsor
Life sciences company with pharmaceuticals, consumer health and crop science divisions.
Talk
Tue Nov 10
09:00–09:30
An Outlook into the Year 2050: Navigating the Future of Efficiency and Innovation
How AI, global expansion and patient community outreach may reshape the way clinical trials are run, and what to change now to prepare.
Panel
Tue Nov 10
15:00–15:25
Inside the Incubator: What It Really Takes to Build a Biotech Company Today
What incubators backed by big drug companies look for in young biotechs, and how they help founders with money, advice and partners.
with Phinomics
Panel
Tue Nov 10
16:30–16:55
The Role of Innovation in Biopharma Growth
How new ideas and technologies drive growth for drug companies, and how to keep innovating while scaling up, with real examples.
Panel
Wed Nov 11
10:00–10:45
AI Regulations: Driving Innovation While Navigating Compliance
What rules cover AI in drug development, where European and US regulators agree, and how rules could help rather than hinder innovation.
with European Medicines Agency
Panel
Wed Nov 11
11:00–12:00
Collaborative Innovation in CDMO Partnerships
How drug companies and contract manufacturers develop new therapies together, with examples of what makes these partnerships work and where they struggle.
with Eleva, Evotec
Boehringer Ingelheim
Ingelheim am Rhein, Germany
◆Platinum Sponsor
Large pharmaPlatinum sponsor
Family-owned pharmaceutical company developing human and animal health medicines.
Panel
Mon Nov 9
13:00–13:45
Open Innovation in Action: How Pharma Is Rewiring the Drug Discovery Ecosystem
How big drug companies share their collections of test molecules and data with outside scientists to speed up early drug discovery.
with MichBio, XGEN Venture, Merck KGaA
Talk
Tue Nov 10
13:00–14:00
Biologics Manufacturing Excellence
How makers of biologics, drugs made in living cells, can expand capacity, clear production bottlenecks and use new technology to work more efficiently.
with Immatics, ValiRx, Pfizer +1 more
Talk
Tue Nov 10
09:30–09:45
Pharma Presentation: Boehringer Ingelheim
Boehringer Ingelheim, independent since 1885, and its research on human and animal medicines for diseases that lack good treatments.
Panel
Wed Nov 11
10:00–10:45
Envisioning the future of ophthalmology
What new data show about treatments for retinal disease, glaucoma and other eye conditions, and where investors see the most promise.
with Micro CRISPR, AAVantgarde Bio, Inveready +1 more
Panel
Wed Nov 11
10:00–10:45
Most Favoured Nations: A Game-Changer for Biotech Dealmaker?
How the US 'most favoured nation' policy, which ties US drug prices to prices paid abroad, is changing drug deals and European launch plans.
with EUCOPE, Bristol Myers Squibb
European Medicines Agency
Amsterdam, Netherlands
Gov, delegations & associations
EU agency that evaluates and supervises medicines for human and veterinary use.
Panel
Mon Nov 9
11:15–12:00
Unlocking Pharma’s Productivity Potential
Why developing medicines keeps getting costlier and slower, and whether AI and research sourced from other companies can make drug companies more productive.
with Norstella, M Ventures, Blackstone Life Sciences +1 more
Business of Biotech
Panel
Tue Nov 10
13:00–13:45
Aligning with Regulators to Propel Innovation
What help and incentives the European Medicines Agency offers developers of new treatments, and how to use them on the road to approval.
with Federal Institute for Drugs and Medical Devices (BfArM), MSD
Panel
Tue Nov 10
14:00–14:45
Harnessing Regulatory Sandboxes to Drive Innovation in Novel Therapeutics & Technologies
How regulatory sandboxes, where regulators let new products be tested under adjusted rules, could support new therapies and health technologies in Europe.
with HTW Berlin, Innovative Health Initiative, CSL Behring
Panel
Wed Nov 11
10:00–10:45
AI Regulations: Driving Innovation While Navigating Compliance
What rules cover AI in drug development, where European and US regulators agree, and how rules could help rather than hinder innovation.
with Bayer
Panel
Wed Nov 11
09:00–09:45
From NAMs (New Approach Methodologies) Innovation to Regulatory acceptance: Accelerating human-relevant modelling
How lab models built on human biology, from organs-on-chips to AI computer models, can speed drug development and win regulators' acceptance.
with FRESCI, Merck KGaA, TissUse +2 more
Informa
London, United Kingdom
Consulting, legal & services
Events, publishing and data group that runs BIO-Europe and publishes BioXconomy.
Keynote
Mon Nov 9
10:15–10:30
Opening Remarks
The Big Picture Plenary Series · with Ministry of Economic Affairs, Industry, Climate Action and Energy of North Rhine-Westphalia, Biotechnology Innovation Organization (BIO)
Talk
Mon Nov 9
09:30–10:00
partneringONE essentials workshop
Newcomers learn what to expect from partnering meetings, including timing and etiquette, and how to get the most from the partneringONE system.
Panel
Tue Nov 10
09:00–09:45
Networks or neurons: What’s next in CNS dealmaking?
What is driving recent deals between biotechs and larger drug companies for brain and nervous system drugs, which remain hard to develop.
with Servier, Biovance Capital, Otsuka +2 more
Talk
Tue Nov 10
11:30–12:00
partneringONE power up workshop
Experienced delegates learn advanced partneringONE features and team habits that save time and raise how often their meeting requests are accepted.
Panel
Wed Nov 11
13:00–13:45
BIO-Europe Media Round-Up: The Stories Shaping Biopharma Right Now
Journalists pick out the biggest biopharma news stories and deal trends of the moment and explain what they mean for dealmakers.
with BioWorld
Panel
Wed Nov 11
09:00–09:45
How is the APAC region reshaping global biopharma?
How China, Japan, South Korea and other Asia-Pacific countries are moving from making drugs to inventing them, and how Western firms can partner.
with MSD, Sinovoy Health Group, WinHealth Pharma +1 more
Biogen
Cambridge, Massachusetts
◆Platinum Sponsor
Large pharmaPlatinum sponsor
Develops and markets therapies for neurological and neurodegenerative diseases, including multiple sclerosis and Alzheimer's disease.
Talk
Mon Nov 9
09:00–10:00
Build, Buy, or Partner? Choosing Your Market Entry Strategy
How drug companies choose between licensing a new product to a regional partner, selling it themselves, or both, with lessons from each path.
with Blue Matter Consulting, Idorsia, Protagonist Therapeutics
Business of Biotech
Panel
Mon Nov 9
13:00–14:00
Navigating partnering and business development in a shifting global landscape
How funding conditions, treatment trends and geopolitics are shaping partnerships and acquisitions between drug and biotech companies, with real deal examples.
with Syneos Health, Genmab, Astellas +2 more
Panel
Tue Nov 10
16:00–16:45
AI and Innovation in Clinical Trials: Transforming Operations and Accelerating Development
How AI can speed clinical trials, from drafting trial plans and finding patients to computer-simulated patients that cut how many real ones are needed.
with PharmSky Research, TransPerfect, Atrogi
Panel
Tue Nov 10
15:00–15:45
Mastering the Shifting Regulatory Landscape: Leveraging the Biotech Act for Innovation and Global Success
How the EU Biotech Act aims to restore Europe's edge through faster trial approvals, quicker rare disease access and proportionate oversight of advanced therapies.
with Roche
Johnson & Johnson
New Brunswick, NJ
◆Platinum Sponsor · Johnson & Johnson Innovation
Large pharmaPlatinum sponsor
Healthcare company developing innovative medicines and medical technologies; its Innovation unit partners with external researchers and start-ups.
Panel
Mon Nov 9
16:15–17:00
Building the Next Global Biotech Hubs: What Makes an Innovation Ecosystem Work?
What makes a region a strong biotech hub, from talent, labs and funding to links with global drug companies.
with 59 North Communications, Gateway Factory, CSL Behring +1 more
Panel
Tue Nov 10
10:00–10:25
Regulatory Updates for Orphan and Pediatric Medicines
How updated EU drug laws change the rewards for rare-disease and children's medicines, such as longer protection from competing copies.
Panel
Wed Nov 11
10:00–10:45
Envisioning the future of ophthalmology
What new data show about treatments for retinal disease, glaucoma and other eye conditions, and where investors see the most promise.
with Micro CRISPR, Boehringer Ingelheim, AAVantgarde Bio +1 more
Panel
Wed Nov 11
12:00–12:45
What's Next for Biomanufacturing Strategies?
Where the manufacturing of biological medicines is heading, from sturdier supply chains and industry mergers to AI and new ways to scale up.
with Resolution Therapeutics, Valneva, IDT Biologika
Novo Nordisk
Bagsværd, Denmark
◆Gold Sponsor
Large pharmaGold sponsor
Danish pharmaceutical company, branded Novo since September 2026, making medicines for diabetes, obesity and rare diseases.
Panel
Mon Nov 9
11:15–12:00
Unlocking Pharma’s Productivity Potential
Why developing medicines keeps getting costlier and slower, and whether AI and research sourced from other companies can make drug companies more productive.
with Norstella, M Ventures, Blackstone Life Sciences +1 more
Business of Biotech
Panel
Tue Nov 10
15:30–15:55
Accelerating Innovation: Creating the Right Environment for Success in Biopharma Partnerships
How to design partnerships that work, from payments tied to research milestones and shared risk to guarding intellectual property while sharing ideas.
Panel
Tue Nov 10
10:00–10:45
Cardiometabolic innovations beyond GLP-1 – Where are we now?
Which drug approaches beyond GLP-1 medicines are drawing attention for obesity, diabetes and heart disease risk, and where money and partnerships are going.
with LifeArc, Atrogi, IsomAb +2 more
Panel
Tue Nov 10
15:00–15:45
Longevity – Are we getting younger?
What recent research shows about treatments that could slow or reverse aging, and how investment in this young field is taking shape.
with Longevity.Technology, Asabys Partners, Chrysea +1 more

Explore the full BIO-Europe 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Cologne. Leave your work email and we’ll be in touch.

Privacy

Download the full BIO-Europe 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find buyers from companies at BIO-Europe 2026

Tell us what you sell and we’ll find the people at these companies most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

When and where was BIO-Europe 2026?

BIO-Europe 2026 ran November 9–11, 2026, at Koelnmesse in Cologne, Germany.

What conference is this?

BIO-Europe is an annual European biotech partnering conference, held November 9–11, 2026 at Koelnmesse in Cologne. Most of its value is in pre-arranged one-to-one partnering meetings between biotech and pharma business-development teams and investors; the program adds panels and talks on the business of biotech, ecosystem innovation, therapeutics, biomanufacturing, clinical and regulatory strategy.

What is in this guide?

Every organization we can place at BIO-Europe 2026: 473 speakers from the public speaker list and agenda (206 sessions) rolled up to their companies and institutions, plus the 127 sponsors, delegations and supporters from the public sponsor list with their tier — 473 organizations in one list. Speakers appear as job titles, never by name. The partnering attendee list needs a login and is not included. A company presentation appears with its time slot once the organizers name the presenting company on the agenda; a presenter whose slot is not named yet is listed with their organization.

How are organizations typed?

By the role an organization plays at a partnering meeting: drug developers (large pharma and biotech), investors, the service providers around them — CDMOs and CROs, tools, data and AI companies, consulting, legal and other services — and academic, government and association bodies, including national and regional delegations. The track filters come from the track an organization speaks in.

How current is it?

Pulled from the public agenda, speaker list and sponsor list on November 10, 2026, while the meeting was under way.

Browse BIO-Europe 2026 by

Organizations with their own page

395 organizations — every exhibitor, every company with talks or known attendees, and every organization with 2 or more presentations.

Not affiliated with or endorsed by BIO-Europe or its organizers. Submit a correction